Impaired functional connectivity of brain reward circuitry in patients with schizophrenia and cannabis use disorder: Effects of cannabis and THC.

PubWeight™: 1.58‹?› | Rank: Top 4%

🔗 View Article (PMID 25037524)

Published in Schizophr Res on July 16, 2014

Authors

Adina S Fischer1, Susan Whitfield-Gabrieli2, Robert M Roth1, Mary F Brunette1, Alan I Green3

Author Affiliations

1: Department of Psychiatry, Geisel School of Medicine at Dartmouth, Hanover, NH, USA.
2: Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA.
3: Department of Psychiatry, Geisel School of Medicine at Dartmouth, Hanover, NH, USA; Department of Pharmacology and Toxicology, Geisel School of Medicine at Dartmouth, Hanover, NH, USA. Electronic address: Alan.I.Green@dartmouth.edu.

Articles cited by this

The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull (1987) 51.07

Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging. Nat Rev Neurosci (2007) 27.23

A component based noise correction method (CompCor) for BOLD and perfusion based fMRI. Neuroimage (2007) 6.01

Functional connectivity of human striatum: a resting state FMRI study. Cereb Cortex (2008) 5.44

The reliability of the Alcohol Timeline Followback when administered by telephone and by computer. Drug Alcohol Depend (1996) 5.35

Conn: a functional connectivity toolbox for correlated and anticorrelated brain networks. Brain Connect (2012) 4.19

Nicotine chemistry, metabolism, kinetics and biomarkers. Handb Exp Pharmacol (2009) 4.16

Co-morbidity of smoking in patients with psychiatric and substance use disorders. Am J Addict (2005) 3.89

Default mode network activity and connectivity in psychopathology. Annu Rev Clin Psychol (2012) 3.49

Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage (2005) 3.48

Anticorrelations in resting state networks without global signal regression. Neuroimage (2011) 3.07

Psychiatric comorbidities and schizophrenia. Schizophr Bull (2008) 2.69

A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry (2001) 2.58

Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction (1999) 2.51

The restless brain. Brain Connect (2011) 2.44

Real-time electronic ambulatory monitoring of substance use and symptom expression in schizophrenia. Am J Psychiatry (2010) 2.09

Endocannabinoid signaling system and brain reward: emphasis on dopamine. Pharmacol Biochem Behav (2005) 2.05

Delay discounting in schizophrenia. Cogn Neuropsychiatry (2007) 1.94

The environment and schizophrenia: the role of cannabis use. Schizophr Bull (2005) 1.90

Psychosis reactivity to cannabis use in daily life: an experience sampling study. Br J Psychiatry (2010) 1.81

Marijuana Craving Questionnaire: development and initial validation of a self-report instrument. Addiction (2001) 1.76

Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol. Handb Exp Pharmacol (2005) 1.63

Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br J Psychiatry (2008) 1.53

Functional connectivity and coactivation of the nucleus accumbens: a combined functional connectivity and structure-based meta-analysis. J Cogn Neurosci (2011) 1.51

The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull (2000) 1.47

Modulation of mediotemporal and ventrostriatal function in humans by Delta9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. Arch Gen Psychiatry (2009) 1.40

Alterations of the brain reward system in antipsychotic naïve schizophrenia patients. Biol Psychiatry (2012) 1.28

Psychotic symptom and cannabis relapse in recent-onset psychosis. Prospective study. Br J Psychiatry (2006) 1.25

Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Harv Rev Psychiatry (1999) 1.21

Medical marijuana: clearing away the smoke. Open Neurol J (2012) 1.21

Impairment of odor hedonics in men with schizophrenia. Am J Psychiatry (2003) 1.13

Disturbances of visual information processing in early states of psychosis and experimental delta-9-tetrahydrocannabinol altered states of consciousness. Schizophr Res (2006) 1.08

Effects of smoked marijuana on social interaction in small groups. Drug Alcohol Depend (1987) 1.04

Substance abuse and schizophrenia: pharmacotherapeutic intervention. J Subst Abuse Treat (2007) 1.03

Ventral striatal activation during attribution of stimulus saliency and reward anticipation is correlated in unmedicated first episode schizophrenia patients. Schizophr Res (2012) 1.02

Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey. J Clin Psychopharmacol (2000) 1.02

Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophr Res (2003) 1.02

A brain on cannabinoids: the role of dopamine release in reward seeking. Cold Spring Harb Perspect Med (2012) 1.00

The vulnerability to alcohol and substance abuse in individuals diagnosed with schizophrenia. Neurotox Res (2006) 1.00

Imaging genetics and the neurobiological basis of individual differences in vulnerability to addiction. Drug Alcohol Depend (2012) 0.94

Ventral striatal activation during reward processing in subjects with ultra-high risk for schizophrenia. Neuropsychobiology (2012) 0.94

Treatment of substance use disorders in schizophrenia: a unifying neurobiological mechanism? Curr Psychiatry Rep (2005) 0.91

Anterior cingulate cortex abnormalities associated with a first psychotic episode in bipolar disorder. Br J Psychiatry (2009) 0.89

Treatment of cannabis use disorders in people with schizophrenia spectrum disorders - a systematic review. Addict Behav (2009) 0.84